Table 1.

Target product profile of developed ASAQ formulation

Attribute	Target product characteristics
API	AS and AQ
Population targeted	pediatric and adult
Posology	based on [7] ASAQ low strength 25/67.5 mg (equivalent AQ base) for children ASAQ high strength 100/270 mg (equivalent AQ base) for older children and adults
Drug release	rapid disintegration and fast drug release (> 75% in 45 minutes in vitro dissolution test, Pharmacopoeia standards)
Drug form	compatible with pediatric use: minimal size for facilitating swallowing; a fixed dose combination
Stability/Conditioning	compatible with climatic zone IV (tropical conditions): ICH Q1A(R2)
Cost	< 1$